This is a working overview of Prohibited substance, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-10 and is reviewed periodically as new material appears.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
have disease progression during or following platinum-containing chemotherapy. have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. On 16 February 2018, the Food and Drug Administration approved durvalumab for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
== Bibliography == Romualdo Verzosa Jr., ed. (1993). Encyclopedia of Chemical Technology, volume 6 (4th ed.). John Wiley & Sons. ISBN 978-0-471-52674-2. Masters, K (1991). Spray Drying Handbook (5th ed.). Longman Scientific & Technical. ISBN 978-0-582-06266-5. John J. McKetta, ed. (1995). Encyclopedia of Chemical Processing and Design. Marcel Dekker Inc. ISBN 978-0-8247-2604-1.
In 1958, the UN established a Good Offices Committee which continued to invite South Africa to bring South West Africa under trusteeship. The Good Offices Committee proposed a partition of the mandate, allowing South Africa to annex the southern portion while either granting independence to the north, including the densely populated Ovamboland region, or administering it as an international trust territory. The proposal met with overwhelming opposition in the General Assembly; fifty-six nations voted against it. Any further partition of South West Africa was rejected out of hand.
mid body The centrally constricted region that forms across the central axis of a cell during cytokinesis, constricted by the closing of the contractile ring until the daughter cells are finally separated, but occasionally persisting as a tether between the two cells for as long as a complete cell cycle.
=== WBSSH definition === The White–Bate-Smith–Swain–Haslam (WBSSH) definition characterized structural characteristics common to plant phenolics used in tanning (i.e., the tannins). In terms of properties, the WBSSH describes the polyphenols as follows:
Sources: en.wikipedia.org
=== 27 April === Ukraine launched a drone attack in Russia's Krasnodar Krai, causing fires in the Ilsky and Slavyansk-on-Kuban oil refineries with 10 drones attacking the Slavyansk-on-Kuban refinery alone. The Kushchyovskaya airbase was also attacked. A number of KAB glide bomb kits were reportedly destroyed along with possibly one Su-34. The Russian MoD claimed to have shot down 66 drones over Krasnodar Krai and two over Crimea. The distillation column of the Slavyansk-on-Kuban refinery was also reported damaged, forcing it to partially suspend operations. The HUR also claimed to have hit a Russian Podlet-K1 radar used to coordinate S-300/400 missile systems.
The researchers found correlations between treatment with antipsychotic drugs and lipid metabolism, in both a lipid-class-specific and drug-specific manner, establishing new foundations around the concept that pharmacometabolomics provides powerful tools for enabling detailed mapping of drug effects. Additional studies by the Pharmacometabolomics Research Network enabled mapping in ways not possible before effects of statins, atenolol and aspirin. Totally new insights were gained about effect of these drugs on metabolism and they highlighted pathways implicated in response and side effects.
In 2013, Michael Klare compared in RealClearPolitics tensions between Russia and the West to the ongoing proxy conflict between Saudi Arabia and Iran. Oxford Professor Philip N. Howard argued that a new cold war was being fought via the media, information warfare, and cyberwar. Some observers, including Syrian president Bashar al-Assad, judged the Syrian civil war to be a proxy war between Russia and the United States, and even a "proto-world war". In January 2016, senior UK government officials were reported to have registered their growing fears that "a new cold war" was now unfolding in Europe: "It really is a new Cold War out there. Right across the EU we are seeing alarming evidence of Russian efforts to unpick the fabric of European unity on a whole range of vital strategic issues". In April 2018, relations deteriorated over a potential US-led military strike in Middle East after the Douma chemical attack in Syria, which was attributed to the Syrian Army by rebel forces in Douma, and poisoning of the Skripals in the UK. The secretary-general of the United Nations, António Guterres, told a meeting of the UN Security Council that "the Cold War was back with a vengeance". He suggested the dangers were even greater, as the safeguards that existed to manage such a crisis "no longer seem to be present". Dmitri Trenin supported Guterres' statement, but added that it began in 2014 and had been intensifying since, resulting in US-led strikes on the Syrian government on 13 April 2018.
The Dutch sprinter Foekje Dillema was expelled from the 1950 national team after she refused a mandatory sex test in July 1950; later investigations revealed a Y-chromosome in her body cells, and the analysis showed that she was probably a 46,XX/46,XY mosaic female. In 1953, a human chimera was reported in the British Medical Journal. A woman was found to have blood containing two different blood types. Apparently this resulted from her twin brother's cells living in her body. A 1996 study found that such blood group chimerism is not rare. In 2002, an article in the New England Journal of Medicine described a woman, later identified as Karen Keegan, in whom tetragametic chimerism was unexpectedly identified after she underwent preparations for kidney transplant. Those preparations for the transplant required the patient and her immediate family to undergo histocompatibility testing, the result of which had suggested that she was not the biological mother of two of her three children. In 2002, Lydia Fairchild was denied public assistance in Washington state when DNA evidence appeared to show that she was not the mother of her children. A lawyer for the prosecution heard of the case of Karen Keegan in New England, and suggested the possibility to the defense, who were able to show that Fairchild, too, was a chimera with two sets of DNA, and that one of those sets could have produced the children. In 2009, singer Taylor Muhl's large torso birthmark was diagnosed as resulting from chimerism.
Wang, N.; He, Y.; Liu, S.; Makarcyzk, M. J.; Lei, G.; Chang, A.; Alexander, P. G.; Hao, T.; Padget, A. M.; De Pedro, N.; Menelaos, T.; Lin, H. (2022). "Engineering Osteoarthritic Cartilage Model". Science China Life Sciences. 65 (2): 309–327. doi:10.1007/s11427-021-1933-7. PMC 10077511. PMID 34109475. S2CID 235393377. Jogi, R.; Tager, M. J.; Perez, D.; Tsapekos, M. (2021). "Bovine Colostrum, Telomeres and Skin aging". Journal of Drugs in Dermatology. 20 (5): 538–545. doi:10.36849/JDD.5851. PMID 33938706. Shafa, M.; Walsh, T.; Panchalingam, K. M.; Richardson, T.; Menendez, L.; Tian, X.; Suresh Babu, S.; Dadgar, S.; Beller, J.; Yang, F.; Baghbaderani, B. A. (2019). "Long-term Stability and Differentiation Potential of Cryopreserved CGMP-compliant Human Induced Pluripotent Stem Cells". International Journal of Molecular Sciences. 21 (1): 108. doi:10.3390/ijms21010108. PMC 6982271. PMID 31877913. Samuel, P.; Tsapekos, M.; De Pedro, N.; Liu, A. G.; Casey Lippmeier, J.; Chen, S. (2022). "Ergothioneine Mitigates Telomere Shortening under Oxidative Stress Conditions". Journal of Dietary Supplements. 19 (2): 212–225. doi:10.1080/19390211.2020.1854919. PMID 33287595. S2CID 227953602. Mehkri, S.; Perez, Diego; Najarro, Pilar; Tsapekos, Menelaos; Bopanna, K. N. (July 2019). "Effect of Lutein (Lute-gen®) on Proliferation Rate and Telomere Length In Vitro and Possible Mechanism of Action". International Journal of Biology Research. 4 (3): 84–91. Phillippe, M.; Sawyer, M. R.; Edelson, P. K. (2019). "The Telomere Gestational Clock". American Journal of Obstetrics and Gynecology.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.